吉非贝齐对不同类型高脂蛋白血症患者脂蛋白浓度的影响。

Effect of gemfibrozil on lipoprotein concentrations in different types of hyperlipoproteinaemia.

作者信息

Olsson A G, Rössner S, Walldius G, Carlson L A

出版信息

Proc R Soc Med. 1976;69 Suppl 2(Suppl 2):28-31. doi: 10.1177/00359157760690S207.

DOI:10.1177/00359157760690S207

PMID:190607

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1864039/

Abstract

The lipoprotein lowering effect of gemfibrozil, 400 mg twice daily, was studied for 24 weeks in 26 subjects with primary hyperlipoproteinaemia (type IIa, 5; IIb, 3; III, 3; and IV, 15). Maximum effects were noted after four weeks on very low density lipoproteins (VLDL) and after 12 weeks on low density lipoproteins (LDL), these effects remaining throughout the study. Gemfibrozil decreased VLDL triglycerides (TG) in all types of hyperlipoproteinaemia according to the equation: deltaVLDL TG (mmol/l) = -0.80 X initial VLDL TG concentration + 0.68 The drug affected the low density lipoprotein (LDL) cholesterol= -0.45 X initial LDL cholesterol + 61 This means that LDL cholesterol on average decreased if the initial LDL concentration was above 135 mg/100 ml and increased below that concentration. LDL TG and high density lipoprotein (HDL) TG concentrations also decreased significantly. A slight increase in HDL cholesterol concentration occurred after administration of gemfibrozil. Two subjects had to stop treatment because of nausea and abdominal pain respectively, attributed to the drug. No biochemical side effects were noted.

摘要

对26例原发性高脂蛋白血症患者（IIa型5例、IIb型3例、III型3例、IV型15例）进行了一项研究，给予吉非贝齐每日两次、每次400mg，疗程24周，以观察其降低脂蛋白的效果。四周时观察到对极低密度脂蛋白（VLDL）的最大效应，12周时观察到对低密度脂蛋白（LDL）的最大效应，且这些效应在整个研究过程中持续存在。吉非贝齐可根据以下公式降低所有类型高脂蛋白血症患者的VLDL甘油三酯（TG）：ΔVLDL TG（mmol/l）=-0.80×初始VLDL TG浓度+0.68。该药物对低密度脂蛋白（LDL）胆固醇的影响为=-0.45×初始LDL胆固醇+61。这意味着，如果初始LDL浓度高于135mg/100ml，LDL胆固醇平均会降低；低于该浓度则会升高。LDL TG和高密度脂蛋白（HDL）TG浓度也显著降低。服用吉非贝齐后，HDL胆固醇浓度略有升高。两名受试者分别因恶心和腹痛而不得不停止治疗，原因归咎于该药物。未观察到生化方面的副作用。